| NCT07142811 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | RECRUITING | PHASE2 | 2025-08-05 | 2031-04 | 2026-11 |
| NCT07128550 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | RECRUITING | PHASE3 | 2025-07-30 | 2031-07 | 2026-12 |
| NCT06960395 | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2025-07-22 | 2029-08 | 2029-08 |
| NCT06903338 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | RECRUITING | PHASE3 | 2025-03-12 | 2031-05 | 2026-12-31 |
| NCT05997615 | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | RECRUITING | PHASE1 | 2023-08-10 | 2027-09-29 | 2027-09-29 |
| NCT05844228 | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 | COMPLETED | PHASE1 | 2023-06-01 | 2025-04-21 | 2025-03-01 |
| NCT05612581 | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-05-10 | 2027-03 | 2026-03 |
| NCT05567783 | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A | TERMINATED | PHASE2 | 2022-10-30 | 2023-08-31 | 2023-05-05 |
| NCT05484206 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | RECRUITING | PHASE1 | 2022-09-21 | 2027-04-30 | 2026-09-25 |
| NCT05461170 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-09-17 | 2029-08 | 2029-08 |
| NCT05356741 | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | RECRUITING | PHASE1, PHASE2 | 2022-04-13 | 2027-08-16 | 2027-08-16 |
| NCT05280717 | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) | TERMINATED | PHASE1 | 2022-03-28 | 2023-11-06 | 2023-04-05 |
| NCT04856085 | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-07-11 | 2027-06 | 2027-06 |
| NCT04988152 | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants | COMPLETED | PHASE1 | 2021-07-06 | 2021-12-07 | 2021-09-02 |
| NCT04913675 | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | TERMINATED | PHASE3 | 2021-06-10 | 2023-03-24 | 2022-07-19 |
| NCT04779879 | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 | COMPLETED | PHASE2 | 2021-02-18 | 2022-04-06 | 2021-08-20 |
| NCT04725877 | VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers | COMPLETED | PHASE1 | 2020-12-28 | 2022-12-05 | 2022-12-05 |
| NCT04545060 | VIR-7831 for the Early Treatment of COVID-19 in Outpatients | COMPLETED | PHASE2, PHASE3 | 2020-08-27 | 2021-09-02 | 2021-04-08 |
| NCT04412863 | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection | COMPLETED | PHASE2 | 2020-07-03 | 2024-03-25 | 2024-03-25 |
| NCT04423393 | Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection | COMPLETED | PHASE1 | 2020-05-26 | 2022-11-25 | 2022-10-24 |
| NCT04033406 | Study of VIR-2482 in Healthy Volunteers | COMPLETED | PHASE1 | 2019-08-26 | 2021-11-01 | 2021-11-01 |
| NCT03672188 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | COMPLETED | PHASE1, PHASE2 | 2018-11-14 | 2020-09-03 | 2020-09-03 |